Cargando…
A History of Targeted Therapy Development and Progress in Novel–Novel Combinations for Chronic Lymphocytic Leukemia (CLL)
SIMPLE SUMMARY: The treatment landscape for CLL has changed dramatically since the advent of targeted therapies. Studies have shown clear progression-free survival (PFS) benefit of these agents, as well as overall survival (OS) benefit in some instances, when compared with chemoimmunotherapy (CIT)....
Autores principales: | Karr, Matthew, Roeker, Lindsey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954076/ https://www.ncbi.nlm.nih.gov/pubmed/36831364 http://dx.doi.org/10.3390/cancers15041018 |
Ejemplares similares
-
Novel-agent combination therapies in chronic lymphocytic leukemia: the law of relative contributions
por: Mato, Anthony R., et al.
Publicado: (2022) -
Immunological aspects in chronic lymphocytic leukemia (CLL) development
por: García-Muñoz, Ricardo, et al.
Publicado: (2012) -
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
por: Odetola, Oluwatobi, et al.
Publicado: (2023) -
Not all lymphoid aggregates in chronic lymphocytic leukemia (CLL) patients are due to CLL!
por: Mahapatra, Lily, et al.
Publicado: (2021) -
Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry
por: Mato, Anthony R., et al.
Publicado: (2019)